⌘K
Loading ticker…
As of 2026-08-24, Bolt Biotherapeutics, Inc. Common Stock (BOLT) has a 3-month relative strength percentile of 17 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 41. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 7.6%, relative volume 0.42×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
BOLT is in a stage 4 downtrend, week 12. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -5.0% / -21.7%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
BOLT appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $29K notional.
Held by 1 ETFs · $29K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $29K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | BOLT Jan avg: 0.68% median: -0.26% win: 50% σ: 11.53% n: 4 2022-04-12 → 2026-07-31 | BOLT Feb avg: -1.04% median: 3.18% win: 50% σ: 16.42% n: 4 2022-04-12 → 2026-07-31 | BOLT Mar avg: -4.29% median: -12.14% win: 25% σ: 18.19% n: 4 2022-04-12 → 2026-07-31 | BOLT Apr avg: -7.77% median: -11.18% win: 40% σ: 24.16% n: 5 2022-04-12 → 2026-07-31 | BOLT May avg: -3.15% median: 8.86% win: 60% σ: 18.18% n: 5 2022-04-12 → 2026-07-31 | BOLT Jun avg: -8.29% median: -8.30% win: 20% σ: 19.31% n: 5 2022-04-12 → 2026-07-31 | BOLT Jul avg: 2.65% median: 3.64% win: 60% σ: 3.64% n: 5 2022-04-12 → 2026-07-31 | BOLT Aug avg: -13.57% median: -13.29% win: 0% σ: 4.90% n: 4 2022-04-12 → 2026-07-31 (current) | BOLT Sep avg: -5.97% median: -4.91% win: 25% σ: 8.87% n: 4 2022-04-12 → 2026-07-31 | BOLT Oct avg: -1.41% median: -3.91% win: 25% σ: 6.71% n: 4 2022-04-12 → 2026-07-31 | BOLT Nov avg: -4.38% median: -5.53% win: 50% σ: 9.62% n: 4 2022-04-12 → 2026-07-31 | BOLT Dec avg: 2.63% median: -2.16% win: 50% σ: 21.86% n: 4 2022-04-12 → 2026-07-31 |